

Bimekizumab 160mg solution for injection in prefilled syringe and pre-filled pen (Bimzelx®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2410	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	28/02/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/bimekizumab-bimzelx-abb-smc2410/>

Other Decision Specified

Date of ADTC 17/11/2021

Selpercatinib 40mg and 80mg hard capsules (Retsevmo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2371	As monotherapy for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.	Not routinely available as not recommended for use in NHS Scotland	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/selpercatinib-retsevmo-nscl-full-smc2371/>

Other Decision Specified

Date of ADTC 17/11/2021

Asfotase alfa 40mg/mL and 100mg/mL solution for injection (Strensiq®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2433	Long-term enzyme replacement therapy in patients with paediatric onset hypophosphatasia to treat the bone manifestations of the disease.	Not routinely available as not recommended for use in NHS Scotland	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/asfotase-alfa-strensiq-nonsub-smc2433/>

Other Decision Specified

Date of ADTC 17/11/2021

Durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2434	Durvalumab in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer.	Not routinely available as not recommended for use in NHS Scotland	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/durvalumab-imfinzi-nonsub-smc2434/>

Other Decision Specified

Date of ADTC 17/11/2021

Ponesimod titration pack and 20mg film-coated tablets (Ponvory®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2384	The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	28/02/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/ponesimod-ponvory-abb-smc2384/>

Other Decision Specified

Date of ADTC 17/11/2021

Osimertinib 40mg and 80mg film-coated tablets (Tagrisso®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2383	As monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIa non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.	Available in line with local or regional guidance	16/02/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/osimertinib-tagrisso-full-smc2383/>

Other Decision Specified

Date of ADTC 17/11/2021

Atezolizumab 840mg and 1,200mg concentrate for solution for infusion (Tecentriq®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2379	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression $\geq 50\%$ tumour cells (TC) or $\geq 10\%$ tumour-infiltrating immune cells (IC) and who do not have epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK) positive NSCLC.	Available in line with local or regional guidance	16/02/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/atezolizumab-tecentriq-full-smc2379/>

Other Decision Specified

Date of ADTC 17/11/2021

Pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2380	As monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.	Available in line with local or regional guidance	16/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-full-smc2380/>

Other Decision Specified

Date of ADTC 17/11/2021

Sebelipase alfa 2mg/mL concentrate solution (Kanuma®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2437	Long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.	Not routinely available as not recommended for use in NHS Scotland	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/sebelipase-alfa-kanuma-nonsub-smc2437/>

Other Decision Specified

Date of ADTC 17/11/2021

Olaparib 100mg and 150mg film-coated tablets (Lynparza®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2435	As monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.	Not routinely available as not recommended for use in NHS Scotland	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-nonsub-smc2435/>

Other Decision Specified

Date of ADTC 17/11/2021

Olaparib 100mg and 150mg film-coated tablets (Lynparza®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2436	As monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.	Not routinely available as not recommended for use in NHS Scotland	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-nonsub-smc2436/>

Other Decision Specified

Date of ADTC 17/11/2021
